Event-Driven Stocks

Benitec Biopharma Inc.

BNTCNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 1 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue—$0$75,000$73,000$59,000$97,000
Operating income−$41.8M−$22.5M−$19.1M−$17.9M−$13.6M−$8.3M
Net income−$37.9M−$21.8M−$19.6M−$18.2M−$13.9M−$8.3M
Total assets$99.6M$52.2M$4.5M$6.0M$21.4M$11.6M
Total liabilities$2.3M$5.0M$4.3M$3.1M$1.4M$1.3M
Equity$97.3M$47.2M$202,000$2.9M$20.0M$10.2M
EPS (diluted)$-1.05$-1.22$-14.12$-37.88$-3.23—
Shares out.26.3M10.6M2.5M8.2M8.2M1.1M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−39.0%
Return on assets
−38.1%
Return on capital (ROCE)
−42.7%
Liabilities / assets
2.3%
Debt / equity
0.02×
Book value / share
$3.71
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
40.56safe
Accruals / assets
−14.4%clean
Piotroski F-Score
4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
59
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 warning● 3 good
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20262.3M23.0-2.9%
Apr 30, 20262.3M21.5+2.3%
Apr 15, 20262.3M21.6-1.7%
Mar 31, 20262.3M13.7+7.1%
Mar 13, 20262.2M8.3+6.7%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)